2. Metabolic Enzyme/Protease Anti-infection
  3. Endogenous Metabolite Bacterial
  4. 2(5H)-Furanone

2(5H)-Furanone  (Synonyms: γ-Crotonolactone)

Cat. No.: HY-W008270 Purity: 99.94%
COA
SDS
Handling Instructions Technical Support

2(5H)-Furanone (γ-Crotonolactone) is an endogenous metabolite. 2(5H)-Furanone mimics N-acyl homoserine lactone signals, occupies the binding site of LuxR homologs, and interferes with quorum sensing-mediated gene regulation. 2(5H)-Furanone inhibits quorum sensing mediated by AHLs with different acyl chain lengths. 2(5H)-Furanone inhibits biofilm formation of environmental Aeromonas hydrophila strains on polystyrene plates. 2(5H)-Furanone suppresses spike-and-wave discharges in a rat model of generalized absence seizures and exhibits selective activity against absence seizures. 2(5H)-Furanone can be used in studies related to bacteria infections and generalized absence seizures.

For research use only. We do not sell to patients.

2(5H)-Furanone

2(5H)-Furanone Chemical Structure

CAS No. : 497-23-4

Size Price Stock Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Liquid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 2(5H)-Furanone:

2(5H)-Furanone Related Antibodies

Top Publications Citing Use of Products

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

2(5H)-Furanone (γ-Crotonolactone) is an endogenous metabolite. 2(5H)-Furanone mimics N-acyl homoserine lactone signals, occupies the binding site of LuxR homologs, and interferes with quorum sensing-mediated gene regulation. 2(5H)-Furanone inhibits quorum sensing mediated by AHLs with different acyl chain lengths. 2(5H)-Furanone inhibits biofilm formation of environmental Aeromonas hydrophila strains on polystyrene plates. 2(5H)-Furanone suppresses spike-and-wave discharges in a rat model of generalized absence seizures and exhibits selective activity against absence seizures. 2(5H)-Furanone can be used in studies related to bacteria infections and generalized absence seizures.[1][2]

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

2(5H)-furanone (0-1 mg/mL; 18 h) dose-dependently inhibits short-chain AHL-mediated quorum sensing in Chromobacterium violaceum CV026[1].
2(5H)-furanone (0.4-1 mg/mL; 12 h) inhibits long-chain AHL-mediated quorum sensing in Agrobacterium tumefaciens NTL-4[1].
2(5H)-furanone (0.2-1 mg/mL; 6 h) inhibits quorum sensing-mediated biofilm formation of Aeromonas hydrophila on polystyrene surfaces[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2(5H)-Furanone Related Antibodies
In Vivo

2(5H)-Furanone (20-200 mg/kg, i.p.; single dose) dose-dependently inhibits γ-butyrolacton (GBL)-induced generalized absence seizures in adult male Sprague-Dawley rats, with an ED50 of 100 mg/kg. It attenuates the GBL-induced potentiation of generalized absence seizures mediated by Muscimol (HY-N2313) in rats, inhibits GBL-induced generalized absence seizures in male postnatal day 10 to 40 juvenile rats, and suppresses Pentylenetetrazole (PTZ)-induced generalized absence seizures in adult male rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 250-300 g, generalized absence seizures induced by intraperitoneal administration of 200 mg/kg γ-butyrolactone)[2]
Dosage: 20 mg/kg; 100 mg/kg; 175 mg/kg; 200 mg/kg (pre-GBL pretreatment); 175 mg/kg (standalone EEG assessment)
Administration: i.p.; single dose
Result: Exhibited dose-dependent suppression of GBL-induced SWD, with an ED50 of 100 mg/kg.
Significantly reduced SWD duration compared to controls at all time points post-GBL administration at 175 mg/kg.
Produced no discernible EEG or behavioral changes when administered alone at 175 mg/kg.
Reduced the muscimol-induced prolongation of GBL-induced SWD duration.
Significantly attenuated muscimol-mediated enhancement of SWD compared to saline-treated controls.
Effectively reduced GBL-induced SWD duration in all age groups tested.
Showed delayed suppressive effect: no significant suppression seen until 40 minutes post-GBL in 26-day-old animals, and 60 minutes post-GBL in animals younger than 26 days.
Significantly suppressed PTZ-induced SWD duration compared to controls at all time points post-PTZ administration.
Molecular Weight

84.07

Formula

C4H4O2
CAS No.
Appearance

Liquid (Density: 1.185 g/cm3)

Color

Colorless to light yellow

SMILES

O=C1OCC=C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (1189.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 11.8948 mL 59.4743 mL 118.9485 mL
5 mM 2.3790 mL 11.8948 mL 23.7897 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (29.74 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (29.74 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.94%

SDS (393 KB)

COA (252 KB) HNMR (119 KB) GC (163 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 11.8948 mL 59.4742 mL 118.9485 mL 297.3712 mL
5 mM 2.3790 mL 11.8948 mL 23.7897 mL 59.4742 mL
10 mM 1.1895 mL 5.9474 mL 11.8948 mL 29.7371 mL
15 mM 0.7930 mL 3.9649 mL 7.9299 mL 19.8247 mL
20 mM 0.5947 mL 2.9737 mL 5.9474 mL 14.8686 mL
25 mM 0.4758 mL 2.3790 mL 4.7579 mL 11.8948 mL
30 mM 0.3965 mL 1.9825 mL 3.9649 mL 9.9124 mL
40 mM 0.2974 mL 1.4869 mL 2.9737 mL 7.4343 mL
50 mM 0.2379 mL 1.1895 mL 2.3790 mL 5.9474 mL
60 mM 0.1982 mL 0.9912 mL 1.9825 mL 4.9562 mL
80 mM 0.1487 mL 0.7434 mL 1.4869 mL 3.7171 mL
100 mM 0.1189 mL 0.5947 mL 1.1895 mL 2.9737 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

2(5H)-Furanone Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

2(5H)-Furanone497-23-4γ-CrotonolactoneEndogenous MetaboliteBacterialquorum sensingAgrobacterium tumefaciens NTL-4Sprague-Dawley ratsChromobacterium violaceum CV026Aeromonas hydrophilarat generalized absence seizure modelsγ-hydroxybutyrateLuxR homologue binding sitesbiofilm formationN-acylhomoserine lactoneInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
2(5H)-Furanone
Cat. No.:
HY-W008270
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.